While MET inhibitors such as crizotinib have shown efficacy in MET-altered non-small cell lung cancer (NSCLC), their role in gastric cancer remains uncertain due to tumor heterogeneity and the lack of robust clinical evidence. The gene discussed is MET; the disease is neoplasm.